Corporate Board Profile
Tech Score: 0/100
| Filing Date | Source Excerpt |
|---|---|
| 2016-05-03 | We entered into a consulting agreement with Dr. Stein effective January 2015. Dr. Stein is responsible for providing us with technical and advisory services related to our research and development efforts. The consulting agreement is effective through January 2020. We have granted Dr. Stein ten-year options to purchase, on a post-Reverse Split basis, 200,000 shares of our Common Stock, at an exercise price of $1.25 per share. The options vest in increments of 1.667% per month on the first day of each calendar month following January, 2015, such that the shares shall be fully vested on January 23, 2020, provided Dr. Stein remains a consultant to us. |
| 2017-05-26 | Robert B. Stein, PhD. MD, Director, joined us effective the closing of the Merger in February, 2016. Dr. Robert B. Stein is Chief Scientific Officer of Agenus Inc. ... Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology & Pharmacology from Duke University. |
| 2018-06-13 | Robert B. Stein, PhD. MD, Director, joined us effective the closing of the Merger in February, 2016. Dr. Robert B. Stein is Chief Scientific Officer of Agenus Inc. ... Dr. Stein began his career at Merck, Sharp and Dohme. He holds an MD and a PhD in Physiology & Pharmacology from Duke University. |
| 2019-08-12 | Robert B. Stein, PhD. MD, Director, joined us effective the closing of the Merger in February, 2016. Dr. Robert B. Stein is Chief Scientific Officer of Agenus Inc. ... Dr. Stein bring substantial scientific expertise to our Board. ... Our Board appointed Messrs. Barrage (Committee Chairperson) and Corvese, and Dr. Stein to the Compensation Committee, all of whom are independent. ... The Nominating and Corporate Governance Committee consists of Joshua Silverman (Chair), Garo Armen, Ph.D., and Robert Stein, Ph.D. ... During fiscal year 2018 we did not compensate directors who were not employees of the Company. |
| 2020-08-28 | Robert B. Stein, Ph.D, MD, Director, joined us effective the closing of the Merger in February, 2016. Dr. Robert B. Stein is Chief Scientific Officer of Agenus Inc. ... Dr. Stein bring substantial scientific expertise to our Board. ... The Science Committee consists of Jennifer Buell, Ph.D. (Chair), Garo H. Armen, Ph.D. and Robert B. Stein, MD, Ph.D. ... During fiscal year 2019 we did not compensate directors who were not employees of the Company. ... We entered into a consulting agreement with Robert B. Stein, PhD, MD, which is described above. |
| 2021-09-08 | Robert B. Stein, Ph.D, MD, Director, joined us effective the closing of the Merger in February, 2016. Dr. Robert B. Stein is Chief Scientific Officer of Agenus Inc. ... Dr. Stein bring substantial scientific expertise to our Board. ... The Science Committee consists of Jennifer Buell, Ph.D., Garo H. Armen, Ph.D. and Robert B. Stein, MD, Ph.D. (Chair). ... The Clinical and Regulatory Committee consists of Jennifer Buell, Ph.D. (Chair), Garo H. Armen, Ph.D. and Robert B. Stein, MD, Ph.D. ... During fiscal year 2020 we did not compensate directors who were not employees of the Company. We entered into a consulting agreement with Robert B. Stein, PhD, MD, which is described above. |
| 2025-03-10 | Robert B. Stein(1) 158,906(3) 3 % |
Data sourced from SEC filings. Last updated: 2026-03-05